You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 信達生物漲5% 獲淡馬錫增持56.85萬股 與來凱醫藥臨牀研究獲批
格隆匯 01-11 11:23
格隆匯1月11日丨信達生物(1801.HK)四日連漲,現漲5.14% ,報45港元,總市值658億港元。來凱醫藥近日宣佈其治療抗PD-1/PD-L1耐藥特定實體瘤患者的聯合治療方案臨牀I/II期試驗申報,已經獲得了中國國家藥品監督管理局藥品審評中心(CDE)的批准。此次臨牀研究獲批,是來凱醫藥與信達生物兩家創新醫藥企業2021年7月建立臨牀研究合作伙伴關係後的一項重要進展。聯合方案採用三個藥物:來凱醫藥的泛AKT抑制劑——處於臨牀開發階段的1類候選新藥afuresertib(LAE002),信達生物的信迪利單抗注射液,以及化療藥物白蛋白結合型紫杉醇或多西他賽。另外,根據聯交所最新權益披露資料顯示,2022年1月5日,信達生物(01801.HK)獲Temasek Holdings (Private) Limited在場內以每股均價40.0037港元增持56.85萬股,涉資約2274.2萬港元。增持後,Temasek Holdings (Private) Limited最新持股數目為117,279,850股,持股比例由7.98%上升至8.02%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account